Physician profile
Marshall Patrick Stagg
NPI 1841281573
$18,736.88
in general payments reported to CMS, 2019-2025
68 companies · $6,615 in 2025
The $6,615 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $736 · 2021: $33.73 · 2022: $2,464 · 2023: $3,268 · 2024: $4,856 · 2025: $6,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Long Term Medical Supply Or Device Loan: $2,283 · Consulting Fee: $1,500 · Education: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,300.88 |
| Long Term Medical Supply Or Device Loan | $2,282.65 |
| Consulting Fee | $1,500.00 |
| Education | $655.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,862.77 | 2019-2025 | |
| Abbvie INC. | $1,759.04 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,492.76 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $991.98 | 2022-2025 | Darzalex, Tecvayli, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $687.03 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Celgene Corporation | $616.87 | 2022-2025 | Reblozyl, Pomalyst, Breyanzi |
| Merck Sharp & Dohme LLC | $582.99 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $526.59 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Eisai INC. | $483.89 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $475.04 | 2019-2024 | Ultomiris |
| Incyte Corporation | $432.19 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Regeneron Pharmaceuticals, INC. | $430.44 | 2024-2025 | Lynozyfic, Libtayo |
| Pfizer INC. | $403.82 | 2022-2025 | |
| Genentech USA, INC. | $398.20 | 2021-2025 | Polivy, Lunsumio, Columvi |
| Gilead Sciences, INC. | $390.01 | 2022-2025 | Trodelvy |
Show all 65 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Stagg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.